Sanjiv Patel, Relay Therapeutics CEO
September 12, 2022 09:02 AM EDTUpdated 10:56 AM
Financing

Re­lay kicks off pub­lic of­fer­ing, seek­ing $300M af­ter lay­ing out ro­bust ES­MO da­ta

Paul Schloesser

Associate Editor

Four days af­ter join­ing the prover­bial win­ner’s cir­cle thanks to its bile duct can­cer drug can­di­date, Re­lay Ther­a­peu­tics is up­ping the ante and look­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times